CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, will host the Ì¢âÂÒDrug Development and Clinical Trial Participation Ì¢âÂÛÏ A Webinar for the Rare Disease CommunityÌ¢âÂÌ_ on September 13, 2013 at 2 p.m. EST. The webinar is an opportunity for parents to learn about the drug development process Ì¢âÂÛÏ from the pre-clinical phase to the clinical phase to the post approval phase and the regulatory process guiding these phases Ì¢âÂÛÏ from industry experts.
Ryan Getzlaf, captain of the Anaheim Ducks, is hosting the third annual Getzlaf Golf Shootout on September 7 and 8 to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy. CureDuchenne is pleased to announce that Patriot Environmental Services, the premier provider of comprehensive environmental services in the southwestern United States, is the title sponsor of the Getzlaf Golf Shootout. Patriot is sponsoring the event in memory of Justin Paul Monastesse who lived with Duchenne for more than 25 years and passed on August 1, 2001.
CureDuchenne, a national nonprofit organization that raises awareness and funds research for Duchenne muscular dystrophy, announced today that Fergie, the eight-time Grammy award-winning singer/songwriter, is appearing in a new public service announcement (PSA) campaign on behalf of the organization. The PSA is part of CureDuchenneÌ¢âÂã¢s efforts to raise awareness of Duchenne, the most common and lethal form of muscular dystrophy, and raise funds to develop a robust pipeline of therapies that target the disease from every angle.
Ryan Getzlaf, captain of the Anaheim Ducks, is hosting the third annual Getzlaf Golf Shootout on September 8 to benefit CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy.
Nine-year-old Tyler Armstrong of Yorba Linda, Calif., is climbing Mt. Baldy on August 17 as a training climb as he prepares to climb Mt. Aconcagua in Argentina, the highest peak (22,837 ft.) in both the Western and Southern Hemispheres, later this year to benefit CureDuchenne. CureDuchenne is a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy.
Sarepta Therapeutics announced today plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the first half of 2014 for the approval of eteplirsen, an exon skipping compound under development for the treatment of Duchenne muscular dystrophy.
CureDuchenne, a nonprofit that raises awareness and funds research to find a cure for Duchenne muscular dystrophy, is proud to be an official charity of the Tinker Bell Half Marathon. The Tinker Bell Half Marathon weekend is January 17-19, 2014. Runners are encouraged to join the CureDuchenne team and help raise funds to find a cure for Duchenne, a progressive muscle-wasting disease. Spots for the Tinker Bell Half Marathon are still available through CureDuchenne.
CureDuchenne, a leader in raising awareness and funding research to find a cure for Duchenne muscular dystrophy, congratulates Prosensa Therapeutics BV on its initial public offering.
CureDuchenne is pleased that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation to drisapersen, an exon-51 skipping compound for the potential treatment of patients with Duchenne Muscular Dystrophy. Drisapersen is being developed by GlaxoSmithKline plc (GSK) and licensed from Prosensa Therapeutics.
